# Intellia Therapeutics, Inc.

**NTLA**

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001652130

**E**

**weakest fifth of 370 graded peers in healthcare**

rank 321 of 370; percentile 86.7; sampling error 2.5 points; lower is stronger

A B C D E

**E, the bear**



| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 77.2 |
| **Solvency** | C<br>percentile 49.4 |
| **Growth and financing** | D<br>percentile 62.9 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $842.1M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway<br>not computable: fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 26, 2026<br>235 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $11.42<br>2026-10-16; market equity $1.6B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 26, 2026*

Intellia Therapeutics, Inc. ("we," "us," "our," "Intellia," or the "Company") is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 77.2** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (1.8%) | (6.6%) | 77.2 | 812 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 4* | | | | | |
| **Solvency, sleeve percentile 49.4** | | | | | |
| Twelve-month failure probability | 0.09% | 0.07% | 56.9 | 247 | 2026-06-30 |
| Altman Z double-prime | (6.12) | (0.30) | 55.0 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 5.08x | 2.96x | 36.1 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 62.9** | | | | | |
| Revenue growth, three-year compound | 9.1% | 10.1% | 52.8 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *a prior annual working-capital observation is required* | | | | | |
| Asset growth, three years | (17.9%) | 2.1% | 80.0 | 705 | 2025-12-31 |
| Net share issuance, one year | 14.1% | 2.5% | 55.9 | 634 | 2026-02-13 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 3.7 months |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 316 | Organon & Co. (OGN) | 85.4 | E | |
| 317 | Sonoma Pharmaceuticals, Inc. (SNOA) | 85.6 | E | dilution, fortress balance sheet |
| 318 | National Vision Holdings, Inc. (EYE) | 85.9 | E | |
| 319 | Natural Alternatives International Inc. (NAII) | 86.2 | E | dilution, late filer, fortress balance sheet |
| 320 | Outset Medical, Inc. (OM) | 86.4 | E | dilution |
| 321 | Intellia Therapeutics, Inc. (NTLA) | 86.7 | E | short runway |
| 322 | DarioHealth Corp. (DRIO) | 87.0 | E | dilution, short runway |
| 323 | Lexaria Bioscience Corp. (LEXX) | 87.3 | E | dilution, short runway, distress |
| 324 | Bristol Myers Squibb Co. (BMY) | 87.7 | E | |
| 325 | Bristol Myers Squibb Co. (CELG-RI) | 87.7 | E | |
| 326 | Intelligent BIO Solutions Inc. (INBS) | 88.1 | E | dilution, short runway |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-16 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (26.3%) | 8.0% | 26 |
| Distance from 52-week high | (59.2%) | (33.0%) | 20 |
| EBIT to enterprise value | not computable | (1.7%) | |
| Free cash flow yield | (24.7%) | (1.0%) | 21 |
| Book value to price | 0.45 | 0.28 | 66 |
| Sales to price | 0.04 | 0.31 | 14 |
| Composite equity issuance, five years | 72.7% | 20.3% | 71 |
| Relative strength against the sector, log excess return | (0.52) | (0.13) | 26 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $106.1M |
| Operating cash flow, four quarters | -$346.6M |
| Months of runway | 3.7 |
| Days since last periodic filing | 74 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $45.7M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $33.1M | 2021-12-31 | 2024-02-22 | 10-K | 24-018736 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $0 | 2021-12-31 | 2022-02-24 | 10-K | 22-001981 |
| 3 | assets | us-gaap:Assets | $1.3B | 2021-12-31 | 2023-02-23 | 10-K | 23-004097 |
| 4 | net income | us-gaap:NetIncomeLoss | -$412.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$394.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 6 | assets | us-gaap:Assets | $842.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 7 | assets | us-gaap:Assets | $1.2B | 2024-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 8 | current assets | us-gaap:AssetsCurrent | $527.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $103.9M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.6B | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$441.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 12 | book equity | us-gaap:StockholdersEquity | $671.4M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 13 | liabilities | us-gaap:Liabilities | $170.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $67.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $57.9M | 2024-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $36.3M | 2023-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $52.1M | 2022-12-31 | 2025-02-27 | 10-K | 25-029007 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-076550 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$348.9M | 2024-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $5.8M | 2024-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$394.1M | 2023-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $14.0M | 2023-12-31 | 2026-02-26 | 10-K | 26-076550 |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$333.3M | 2022-12-31 | 2025-02-27 | 10-K | 25-029007 |
| 24 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $13.6M | 2022-12-31 | 2025-02-27 | 10-K | 25-029007 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $6.2M | 2016-12-31 | 2019-02-27 | 10-K | 19-004680 |
| 26 | depreciation amortization | us-gaap:Depreciation | $1.1M | 2016-12-31 | 2018-03-14 | 10-K | 18-005544 |
| 27 | operating income | us-gaap:OperatingIncomeLoss | -$32.2M | 2016-12-31 | 2019-02-27 | 10-K | 19-004680 |
| 28 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$31.6M | 2016-12-31 | 2018-03-14 | 10-K | 18-005544 |
| 29 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2016-12-31 | 2017-03-14 | 10-K | 17-082186 |
| 30 | current assets | us-gaap:AssetsCurrent | $281.3M | 2016-12-31 | 2018-03-14 | 10-K | 18-005544 |
| 31 | current liabilities | us-gaap:LiabilitiesCurrent | $30.7M | 2016-12-31 | 2018-03-14 | 10-K | 18-005544 |
| 32 | assets | us-gaap:Assets | $1.3B | 2023-12-31 | 2025-02-27 | 10-K | 25-029007 |
| 33 | assets | us-gaap:Assets | $1.5B | 2022-12-31 | 2024-02-22 | 10-K | 24-018736 |
| 34 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 118,133,546 | 2026-02-13 | 2026-02-26 | 10-K | 26-076550 |
| 35 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 103,517,460 | 2025-02-14 | 2025-02-27 | 10-K | 25-029007 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.